Home
    Disclaimer
    ← Back to 5-MeO-AMT
    5-MeO-AMT molecular structure

    5-MeO-AMT Stats & Data

    Psychedelic Stimulant Empathogen Research-chemical
    Alpha Alpha-o Α,o-dms Α,o-dimethylserotonin 5meoamt 5-MeO-αMT
    NPS DataHub
    MW204.27
    FormulaC12H16N2O
    CAS1137-04-8
    IUPAC1-(5-methoxy-1~{H}-indol-3-yl)propan-2-amine
    SMILESCOc1ccc2ncc(CC(C)N)c2c1
    InChIKeyOGNJZVNNKBZFRM-QMMMGPOBSA-N
    Tryptamines; 2020/5.1 Indol-3-alkylamine; 2021/5.1 Indol-3-alkylamine; 2022/5.1 Indol-3-alkylamine
    Chemical Class Tryptamine
    Psychoactive Class Psychedelic / Stimulant
    Half-Life Unknown in humans; no robust, peer‑reviewed human pharmacokinetic data are available. Long subjective duration suggests slow clearance and/or active metabolites, but direct half‑life estimates are not established.

    Effect Profile

    Curated + 144 Reports
    Psychedelic 6.5

    Strong visuals, auditory effects, and body load with mild headspace

    Visual Intensity×3
    10104.1
    Headspace Depth×3
    45.010
    Auditory Effects×1
    10102.5
    Body Load / Somatic Effects×1
    10108.1
    Catalog Erowid BlueLight
    Empathogen 9.4

    Strong empathy, stimulation, sensory enhancement, and euphoria

    Empathy / Social Openness×3
    103.82.5
    Euphoria / Mood Elevation×2
    85.75.4
    Stimulation×1
    105.110
    Sensory Enhancement×1
    10105.0
    Catalog Erowid BlueLight
    Stimulant 5.8

    Strong anxiety/jitters, stimulation, and euphoria with low focus

    Stimulation / Energy×3
    86.0
    Euphoria / Mood Lift×2
    84.7
    Focus / Productivity×2
    33.8
    Anxiety / Jitters×1
    1010
    Catalog Erowid
    Based on reports from:
    Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 5-MeO-AMT

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    30 minutes - 2.0 hours
    1-2 hours
    3-8 hours
    3-6 hours
    4-24 hours
    Insufflated
    4-19 minutes
    19-40 minutes
    3-8 hours
    3-6 hours
    4-24 hours
    Rectal
    4-19 minutes
    30 minutes - 1.0 hours
    3-8 hours
    3-6 hours
    4-24 hours

    Empirical Duration

    Erowid Reports
    Onset Come Up Peak Offset
    Oral (24 reports)

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; no robust, peer‑reviewed human pharmacokinetic data are available. Long subjective duration suggests slow clearance and/or active metabolites, but direct half‑life estimates are not established.
    Addiction Potential
    Low. No clear evidence for physical dependence; psychological habituation is possible. Animal data show hallucinogen-like discriminative stimulus without psychostimulant-like reinforcement, suggesting low abuse liability, but long duration and stimulation can encourage risky redosing in inexperienced users.

    Tolerance Decay

    Full tolerance 0h Half tolerance 3d Baseline ~10d

    Animal data show rapid tolerance to head-twitch with repeated dosing; users commonly report diminished effects for several days after use with partial recovery by ~3 days and near-baseline after ~10–14 days. Cross-tolerance with classic psychedelics is expected given shared 5‑HT2A agonism, but human quantification is lacking.

    Cross-Tolerances

    LSD
    50% ●○○
    Psilocybin
    50% ●○○
    DMT
    40% ●○○

    Experience Report Analysis

    Erowid BlueLight
    136 Reports
    2000–2019 Date Range
    12 With Age Data
    32 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 144 experience reports (136 Erowid + 8 Bluelight)

    144 Reports
    86 Effects Detected
    31 Positive
    44 Adverse
    11 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 31

    Brightness Enhancement 37.5% 87%
    Melting/flowing 37.5% 83%
    Thought Acceleration 37.5% 80%
    Surface Breathing 37.5% 85%
    Patterning 37.5% 83%
    Stimulation 35.4% 81%
    Euphoria 32.6% 86%
    Music Enhancement 31.2% 90%
    Color Enhancement 30.5% 84%
    Tactile Enhancement 27.1% 80%
    Visual Trails 25.0% 88%
    Joy 25.0% 80%
    Geometric Imagery 25.0% 82%
    Awe 25.0% 78%
    Auditory-Visual Synesthesia 25.0% 82%
    Empathy 18.7% 80%
    Focus Enhancement 18.7% 75%
    Body High 15.3% 85%
    Tessellation 12.5% 80%
    Sociability Enhancement 12.5% 85%

    Adverse Effects 44

    Body Load 62.5% 81%
    Nausea 57.0% 87%
    Anxiety 41.6% 78%
    Vomiting 37.5% 92%
    Diarrhea 37.5% 82%
    Insomnia 37.5% 88%
    Dizziness 25.0% 90%
    Depersonalization 25.0% 82%
    Confusion 21.3% 70%
    Headache 20.2% 75%
    Pupil Dilation 16.0% 83%
    Muscle Tension 13.2% 70%
    Dry Mouth 12.5% 75%
    Stomach Cramps 12.5% 75%
    Thought Disorganization 12.5% 75%
    Body Temperature Change 12.5% 70%
    Chills 12.5% 80%
    Focus Suppression 12.5% 80%
    Sociability Suppression 12.5% 75%
    Libido Suppression 12.5% 85%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    Insufflated

    View data table
    Effect Threshold (n=14)
    Visual Distortions 78.6%
    Nausea 71.4%
    Stimulation 50.0%
    Music Enhancement 42.9%
    Sedation 35.7%
    Tactile Enhancement 35.7%
    Hospital 35.7%
    Euphoria 35.7%
    Confusion 35.7%
    Anxiety 35.7%
    Color Enhancement 28.6%
    Focus Enhancement 28.6%
    Closed-Eye Visuals 21.4%
    Dissociation 21.4%
    Auditory Effects 21.4%

    Oral

    View data table
    Effect Strong (n=18) Heavy (n=45)
    Visual Distortions 88.9% 82.2%
    Nausea 50.0% 68.9%
    Euphoria 55.6% 26.7%
    Anxiety 38.9% 53.3%
    Tactile Enhancement 50.0% 28.9%
    Color Enhancement 38.9% 37.8%
    Stimulation 22.2% 37.8%
    Focus Enhancement 33.3% 20.0%
    Headache 33.3% 31.1%
    Music Enhancement 22.2% 31.1%
    Sedation 16.7% 28.9%
    Confusion 22.2% 26.7%
    Muscle Tension 22.2% 15.6%
    Pupil Dilation 22.2% 13.3%
    Auditory Effects 22.2% 22.2%

    Subjective Effect Ontology

    Experience Reports

    Structured effect tags extracted from 144 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

    Visual

    visual distortions 107 74.3%

    1 unique effects extracted · Derived from Erowid & Bluelight reports

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 136 experience reports.

    Insufflated dose range: 4.0–20.0 mg (median 12.0 mg)
    Effect Threshold (n=14)
    visual distortions
    79%
    nausea
    71%
    stimulation
    50%
    music enhancement
    43%
    sedation
    36%
    tactile enhancement
    36%
    hospital
    36%
    euphoria
    36%
    confusion
    36%
    anxiety
    36%
    color enhancement
    29%
    focus enhancement
    29%
    closed-eye visuals
    21%
    dissociation
    21%
    auditory effects
    21%
    empathy
    21%
    memory suppression
    21%
    introspection
    14%
    jaw clenching
    14%
    open-eye visuals
    14%

    Showing top 20 of 24 effects

    Oral dose range: 5.0–13.0 mg (median 6.0 mg)
    Effect Strong (n=18) Heavy (n=45)
    visual distortions
    89%
    82%
    		→
    nausea
    50%
    69%
    		↑
    euphoria
    56%
    27%
    		↓
    anxiety
    39%
    53%
    		↑
    tactile enhancement
    50%
    29%
    		↓
    color enhancement
    39%
    38%
    		→
    stimulation
    22%
    38%
    		↑
    focus enhancement
    33%
    20%
    		↓
    headache
    33%
    31%
    		→
    music enhancement
    22%
    31%
    		↑
    sedation
    17%
    29%
    		↑
    confusion
    22%
    27%
    		↑
    muscle tension
    22%
    16%
    		↓
    pupil dilation
    22%
    13%
    		↓
    auditory effects
    22%
    22%
    		→
    empathy
    17%
    20%
    		↑
    hospital
    17%
    16%
    		→
    ego dissolution
    17%
    16%
    		→
    jaw clenching
    17%
    4%
    		↓
    closed-eye visuals
    17%
    16%
    		→

    Showing top 20 of 31 effects

    Risk Escalation

    Sentiment Analysis

    Average frequency of positive vs adverse effects across dose tiers (Oral)

    Strong n=18
    10 positive 27.2% 8 adverse 27.1%
    Heavy n=45
    9 positive 25.4% 12 adverse 21.5%
    View effect breakdown

    Adverse Effects

    Effect Strong (n=18) Heavy (n=45) Change
    Nausea
    50%
    69%
    		+37%
    Anxiety
    39%
    53%
    		+37%
    Headache
    33%
    31%
    		-6%
    Confusion
    22%
    27%
    		+20%
    Muscle Tension
    22%
    16%
    		-29%
    Pupil Dilation
    22%
    13%
    		-40%
    Jaw Clenching
    17%
    4%
    		-73%
    Memory Suppression
    11%
    13%
    		+19%
    Motor Impairment —
    9%
    		0%
    Sweating —
    9%
    		0%
    Increased Heart Rate —
    7%
    		0%
    Psychosis —
    7%
    		0%

    Positive Effects

    Effect Strong (n=18) Heavy (n=45) Change
    Euphoria
    56%
    27%
    		-51%
    Tactile Enhancement
    50%
    29%
    		-42%
    Color Enhancement
    39%
    38%
    		-2%
    Stimulation
    22%
    38%
    		+70%
    Focus Enhancement
    33%
    20%
    		-39%
    Music Enhancement
    22%
    31%
    		+40%
    Empathy
    17%
    20%
    		+19%
    Introspection
    11%
    16%
    		+40%
    Body High
    11%
    11%
    		0%
    Creativity Enhancement
    11%
    		— 0%

    Dosage Distribution

    Dose distribution from experience reports

    Insufflated

    Median: 12.0 mg IQR: 4.0–20.0 mg n=14

    Oral

    Median: 6.0 mg IQR: 5.0–13.0 mg n=71

    Real-World Dose Distribution

    62K Doses

    From 159 individual dose entries

    Insufflated (n=21)

    Median: 6.0mg 25th: 3.0mg 75th: 20.0mg 90th: 20.0mg
    mg/kg median: 0.138 mg/kg 75th: 0.276

    Oral (n=118)

    Median: 6.0mg 25th: 5.0mg 75th: 11.5mg 90th: 17.15mg
    mg/kg median: 0.079 mg/kg 75th: 0.148

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Insufflated

    Median: 0.165 mg/kg IQR: 0.061–0.277 mg/kg n=13

    Oral

    Median: 0.083 mg/kg IQR: 0.057–0.147 mg/kg n=67

    Redose Patterns

    Redosing behavior across 109 reports

    19.3% Redosed
    1.3 Avg Doses
    120m Median Interval
    Read full reports on Erowid →

    Harm Reduction

    drugs.wiki

    • Dose sensitivity is extreme at the milligram level; 5–8 mg oral has been associated with medical emergencies in community reports. Use a calibrated 0.001 g (milligram) scale and avoid volumetric errors. • Onset can be delayed to 90–120 minutes orally; redosing during the come-up is a common error that can produce protracted, dysphoric overstimulation and medical crises. • Insufflation is overrepresented in problem reports and can cause severe local irritation and systemic side effects; if used at all, doses must be markedly reduced compared with oral. • Material has been mis-sold as LSD or confused with AMT; paper blotter or drops have historically contained 5‑MeO‑AMT. Always reagent-test and, where available, use laboratory drug checking before ingestion. • Sympathomimetic effects (tachycardia, mydriasis, sweating, tremor, hypertension) are common; those with cardiovascular disease, seizure history, or uncontrolled hypertension should avoid. • Avoid combinations with MAOIs, MDMA, DXM, and serotonergic antidepressant stacks due to serotonin toxicity/hyperthermia risks; several severe intoxications and at least one death have been linked to high/unknown-dose 5‑MeO‑AMT, sometimes initially misattributed to LSD. • Plan for a very long tail of stimulation and potential insomnia; do not drive or operate machinery until fully baseline (commonly the day after, or longer at higher doses). • If severe agitation, hyperthermia, chest pain, confusion, or seizures occur, seek emergency care promptly; do not attempt to self-treat with additional substances. • Repeated administration over days shows rapid tolerance in animals; practical cross-tolerance with classic psychedelics is likely—space sessions by at least 10–14 days. • Because human pharmacokinetics are uncharacterized, start low, avoid stacked doses, and ensure a trusted sober sitter and a cool environment with hydration. • Where possible, use professional drug checking services to confirm identity/purity; field reagents (Ehrlich/Hofmann) can help rule in indoles and rule out NBOMes on blotter but are not definitive. • Avoid mixing with heavy exercise, hot environments, or dehydration, which can increase hyperthermia risk. • Store securely and label clearly to prevent confusion with AMT or other tryptamines.

    References

    Drugs.wiki References

    ← Back to 5-MeO-AMT